Evidence level: B
「虚则受邪」翻译成统计语言就是交互项。但交互项是统计学里出了名的低功效检验,而基线 25(OH)D 这个修饰变量自己有三个身份——被测错、随暴露移动、被疾病反向压低。三者叠加,这个检验最可能给出的不是答案,是沉默。
正文
上一篇(基线维生素D状态的效应修饰)把「效应修饰」这个概念立了起来:补同样的维生素D,基线 25(OH)D 低于 25 nmol/L 的人急性呼吸道感染风险降低 42%(OR 0.58),而 ≥25 nmol/L 的人没有获益(OR 0.89,95%CI 0.77-1.04)(PMID 28202713);芬兰 RCT 里无论分组,基线 <50 nmol/L 者的感染风险是充足者的 2.1 倍(PMID 39301110)。这些证据说的是「基线状态决定易感性」。
现在要问一个更严格的问题:能不能把「太阳周期相位」当暴露、把「基线 25(OH)D」当修饰变量,显式建一个交互项,直接检验「缺乏亚组中太阳-疾病关联强度是否显著高于充足亚组」? 这个问题在统计上完全合法。但要穿过三道墙,每一道都会把结论削薄。
第一道墙:交互项天生低功效。 Brookes 等用模拟算过一笔账(PMID 15066682):一个对主效应有 80% 功效的试验,对「与主效应同量级」的交互项只有 29% 功效;要让交互项达到同等功效,样本量要放大四倍,交互效应小于主效应 20% 时样本量需求急剧膨胀。这不是理论担忧,是实测分布。Sun 等系统评阅 207 个报告亚组分析的 RCT(PMID 22422832):64 个(31%)在摘要里做了亚组断言,其中只有 6 个(9%)做了统计学显著的交互检验,只有 4 个(6%)事前正确指定了效应方向,19 个多断言的试验里只有 1 个(5%)检验了交互项之间的独立性。更硬的一篇(PMID 28192563):117 条亚组断言中 46 条(39.3%)有显著交互,其中只有 1 条(2.2%)做了多重检验校正,只有 5 条(10.9%)后来被独立复现尝试过——而这 5 次复现全部没能重现原来的亚组效应,且所有效应量都向零衰减。
第二道墙:修饰变量自己的三个身份。
身份一,它被测错。 单次 25(OH)D 测量并不代表长期状态。Major 等在 538 人里做年内两次重复测量(PMID 23144464):类内相关系数 ICC = 0.72,去衰减因子 1.39——意思是用单次测量做回归,关联会被衰减掉约 40%。而交互项对暴露测量误差的敏感度高于主效应:Greenwood 等证明交互项系数会被暴露测量误差偏倚(PMID 16674808);Aschard 等进一步给出量级——环境变量测量误差造成「功效大幅下降 + 交互估计系统性偏零」(PMID 29424028)。
身份二,它随暴露一起移动。 25(OH)D 本身就是 UVB 暴露的产物。用它当修饰变量去检验 UVB 暴露的效应,等于用暴露的下游指标给暴露分层。太阳周期是 11 年尺度、25(OH)D 是季节尺度,两个时间尺度不同,所以操作上并非不可行(同一周期相位下,个体 25(OH)D 差异由纬度、肤色、补充剂、GC 基因型决定,PMID 33230496)。但不能忽视:若在太阳活动低年采样,整个样本的 25(OH)D 都被压低。分层变量随暴露移动,意味着「缺乏组」里的人是随时间换的——交互项混合了「谁」和「何时」两个问题。
身份三,它被结局反向压低。 RCT 方法学已明确指出,25(OH)D 与疾病的关系会被「疾病本身降低血清 25(OH)D」混淆(PMID 28842142)。当修饰变量与结局共变,交互项就不再是纯粹的易感性标记。
第三道墙:尺子问题。 即便交互项被检出,「缺乏组更敏感」这句话仍需要一个标度。Knol 与 VanderWeele 给出四步呈现模板(PMID 22253321),第一步就是把四个格子的风险(RR/OR/RD)全部摆出来——因为同一批数据在加性尺度和乘性尺度上可以得出方向相反的结论。加性交互的标准度量是 RERI(PMID 19211620),它等于线性 OR 模型里的乘积项,与逻辑回归输出的乘积项不是一回事。只报一个乘积项 p 值的研究,其实回答了一个它从未声明的标度问题。
已有的正面证据长什么样? 25(OH)D 的效应修饰确实在别的结局上被验出来过,形态值得抄:护士健康研究里,25(OH)D 与冠心病的关系在甲状旁腺素(PTH)高的人中存在(最高 vs 最低四分位 OR 0.43),PTH 低的人里没有(OR 1.28),交互 P = 0.02(PMID 28882871);1926 人随访 36 个月,25(OH)D × 空腹血糖的乘性交互 P = 0.005,与年龄的加性交互 RERI = 0.897(PMID 36643972);NHANES 7511 人,睡眠模式修饰 25(OH)D 与冠心病的关系(PMID 36863481);VITAL 结直肠腺瘤亚研究,补充 × 基线 25(OH)D 的交互 P = 0.07(普通腺瘤)、P = 0.04(进展期腺瘤)(PMID 32062040);5110 人的补充试验里,基线 25(OH)D、BMI、日照时长显著修饰「补充后 25(OH)D 的应答」(交互 P 均 <0.05),而族裔、吸烟、剧烈运动不修饰(PMID 32360596)。共同点:这些都是「同一个体层面两个变量之间」的修饰,而不是「宏观周期相位」当暴露的修饰。 后者至今没有一个直接检验——不是没人想做,是难做。
如果真要测,必须事前钉死四件事:① 样本量按交互项算而不是按主效应算(PMID 15066682 的四倍规则),并先估算「缺乏组」占比与亚组内事件数;② 加性与乘性两种标度都报,并把四个格子的风险摆出来(PMID 22253321);③ 用重复测量或对单次测量做衰减校正(PMID 23144464);④ 用跨层次设计思路处理「暴露在群体/时期层面、结局在个体层面」时同时出现的组水平混杂与层内相关(PMID 10814658)。
证据与局限
已验证: 交互项检验功效远低于主效应(同量级交互需样本量×4,PMID 15066682);已发表亚组断言的复现率极低且效应量向零衰减(PMID 28192563);单次 25(OH)D 测量衰减关联约 40%(PMID 23144464);暴露测量误差使交互估计偏零(PMID 16674808、PMID 29424028);加性与乘性交互须分别报告(PMID 22253321、PMID 19211620);25(OH)D 的效应修饰在 PTH、空腹血糖、睡眠、BMI/日照等变量上已被检出(PMID 28882871、PMID 36643972、PMID 36863481、PMID 32062040、PMID 32360596);跨层次生态暴露与个体结局的效应修饰存在组水平混杂与层内相关(PMID 10814658)。
部分验证: 「缺乏者占比不同导致太阳-疾病效应量漂移」是异质性来源的候选机制之一;基线 25(OH)D 的可分层性由纬度、肤色、补充剂、GC 基因型共同决定(PMID 33230496、PMID 31669447);基线 25(OH)D 与效应修饰的关系在维生素D轴内已被多次检出,但方向与量级随结局变化。
待验证: 太阳周期相位 × 基线 25(OH)D 的显式交互项从未被直接建模;「修饰变量随暴露移动」造成的分层漂移量级未知;跨纬度梯度是否放大交互效应未测;加性/乘性两尺度结论一致率能否作为新交互项成立的前置筛,尚无系统评估。
相关阅读
- 同样的太阳,为什么有人受邪有人无感?基线维生素D状态的效应修饰
- 血清维生素D:太阳周期影响健康的中介通道有多大分量?
- 太阳活动效应的跨纬度多中心直接对比
- 五运六气=气候周期医学
- 研究池子:环境-生命频率接口
证据等级: B(方法学与效应修饰证据均有 PubMed 直接支撑;「太阳周期相位 × 基线 25(OH)D 交互项」本身尚无直接研究,属方法学延伸论证)
参考文献: PMID 15066682, PMID 22422832, PMID 28192563, PMID 23144464, PMID 16674808, PMID 29424028, PMID 22253321, PMID 19211620, PMID 28882871, PMID 36643972, PMID 36863481, PMID 32062040, PMID 32360596, PMID 10814658, PMID 28202713, PMID 39301110, PMID 33230496, PMID 28842142, PMID 31669447
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Do People Lacking Vitamin D Experience Greater Solar Influence? The Triple Identity Trap in Testing the Interaction Between Solar Cycles and Baseline Vitamin D
Evidence level: B
“Xu Ze Shou Xie” (deficiency attracts pathogenicity) translates into statistical language as an interaction term. Yet, interaction terms are notoriously low-power tests in statistics, while the baseline 25(OH)D modifier variable itself holds three identities: measured incorrectly, moving with exposure, and suppressed by the outcome. When all three stack, this test is most likely to yield not an answer, but silence.
Main Text
The previous article (Effect Modification by Baseline Vitamin D Status) established the concept of effect modification: with the same vitamin D supplementation, individuals with baseline 25(OH)D < 25 nmol/L experienced a 42% reduction in acute respiratory infection risk (OR 0.58), whereas those with ≥25 nmol/L showed no benefit (OR 0.89, 95%CI 0.77-1.04) (PMID 28202713); in a Finnish RCT, regardless of group assignment, infection risk for those with baseline <50 nmol/L was 2.1 times that of sufficient individuals (PMID 39301110). This evidence speaks to “baseline status determines susceptibility.”
Now we must ask a stricter question: Can we explicitly construct an interaction term treating “Solar Cycle Phase” as the exposure and “Baseline 25(OH)D” as the modifier to directly test whether the strength of the solar-disease association is significantly higher in the deficiency subgroup than in the sufficient subgroup? This question is statistically legitimate. However, it must pass through three walls, each thinning the conclusion.
Wall One: Interaction Terms Are Innately Low-Power. Brookes et al. calculated this with simulations (PMID 15066682): a trial with 80% power for the main effect has only 29% power for an interaction term of similar magnitude; to achieve equivalent power for the interaction, sample size must be quadrupled, and requirements expand drastically when the interaction effect is less than 20% of the main effect. This is not theoretical concern but empirical distribution. Sun et al., in a systematic review of 207 RCTs reporting subgroup analyses (PMID 22422832), found that while 64 (31%) made subgroup assertions in abstracts, only 6 (9%) performed statistically significant interaction tests, only 4 (6%) pre-specified the effect direction, and in 19 trials with multiple assertions, only 1 (5%) tested independence between interaction terms. A harder study (PMID 28192563) found that among 117 subgroup assertions, 46 (39.3%) showed significant interactions; of these, only 1 (2.2%) underwent multiple testing correction, and only 5 (10.9%) were subsequently attempted for independent replication—and all five replications failed to reproduce the original subgroup effects, with all effect sizes attenuating toward zero.
Wall Two: The Three Identities of the Modifier Variable.
Identity One, It Is Measured Incorrectly. A single 25(OH)D measurement does not represent long-term status. Major et al., across 538 individuals with two repeated measurements within a year (PMID 23144464), found an intraclass correlation coefficient ICC = 0.72 and a attenuation factor of 1.39—meaning using single measurements in regression attenuates associations by approximately 40%. Interaction terms are more sensitive to exposure measurement error than main effects: Greenwood et al. demonstrated that interaction coefficients are biased by exposure measurement error (PMID 16674808); Aschard et al. further quantified the magnitude—environmental variable measurement error causes “drastically reduced power + systematic bias toward zero in interaction estimation” (PMID 29424028).
Identity Two, It Moves With Exposure. 25(OH)D is itself a product of UVB exposure. Using it as a modifier to test UVB exposure effects equals stratifying by a downstream indicator of the exposure. The solar cycle operates on an 11-year scale, while 25(OH)D is seasonal; differing time scales make this operationally feasible (individual 25(OH)D differences under the same cycle phase are determined by latitude, skin pigmentation, supplementation, and GC genotype, PMID 33230496). However, one cannot ignore: if sampling occurs during low solar activity years, the entire sample’s 25(OH)D levels are suppressed. When a stratification variable moves with exposure, it implies that individuals in the “deficiency group” change over time—the interaction term conflates “who” and “when.”
Identity Three, It Is Suppressed by the Outcome. Methodological guidelines for RCTs explicitly state that the relationship between 25(OH)D and disease is confounded by “the disease itself lowering serum 25(OH)D” (PMID 28842142). When a modifier variable covaries with the outcome, the interaction term ceases to be a pure marker of susceptibility.
Wall Three: The Scale Problem. Even if an interaction is detected, the statement “deficiency groups are more sensitive” requires a scale. Knol and VanderWeele provide a four-step presentation template (PMID 22253321), starting with displaying the risks (RR/OR/RD) for all four cells—because the same dataset can yield opposite conclusions on additive versus multiplicative scales. The standard measure for additive interaction is RERI (PMID 19211620), which equals the product term in a linear odds ratio model but differs from the product term output by logistic regression. Studies reporting only a product term p-value actually answer a scaling question they never declared.
What Does Existing Positive Evidence Look Like? Effect modification by 25(OH)D has been verified on other outcomes, with forms worth copying: In the Nurses’ Health Study, the relationship between 25(OH)D and coronary heart disease exists in individuals with high parathyroid hormone (PTH) (highest vs. lowest quartile OR 0.43) but not in those with low PTH (OR 1.28), with interaction P = 0.02 (PMID 28882871); in a 36-month follow-up of 1926 individuals, the multiplicative interaction of 25(OH)D × fasting glucose had P = 0.005, while the additive interaction with age yielded RERI = 0.897 (PMID 36643972); in NHANES with 7,511 individuals, sleep patterns modified the relationship between 25(OH)D and coronary heart disease (PMID 36863481); in the VITAL colorectal adenoma substudy, the interaction of supplementation × baseline 25(OH)D had P = 0.07 (ordinary adenoma) and P = 0.04 (advanced adenoma) (PMID 32062040); in a supplementation trial with 5,110 individuals, baseline 25(OH)D, BMI, and sun exposure duration significantly modified “response to supplementation” (interaction P < 0.05 for all), whereas ethnicity, smoking, and vigorous exercise did not modify (PMID 32360596). Commonality: These are all modifications between “two variables at the individual level,” not “macroscopic cycle phases” as exposures. The latter has never been directly tested—not that no one wants to, but it is difficult.
If testing is truly required, four things must be fixed in advance: ① Calculate sample size based on interaction terms rather than main effects (PMID 15066682 quadrupling rule), and first estimate the proportion of “deficiency groups” and event counts within subgroups; ② Report both additive and multiplicative scales, displaying risks for all four cells (PMID 22253321); ③ Use repeated measurements or apply attenuation correction to single measurements (PMID 23144464); ④ Apply cross-level design approaches to handle simultaneous group-level confounding and within-level correlation when “exposure is at the group/time level but outcome is at the individual level” (PMID 10814658).
Evidence and Limitations
Verified: Interaction test power is far lower than main effects (same-magnitude interaction requires sample size ×4, PMID 15066682); replication rate of published subgroup assertions is extremely low with effect sizes attenuating toward zero (PMID 28192563); single 25(OH)D measurements attenuate associations by ~40% (PMID 23144464); exposure measurement error biases interaction estimates toward zero (PMID 16674808, PMID 29424028); additive and multiplicative interactions must be reported separately (PMID 22253321, PMID 19211620); effect modification by 25(OH)D has been detected on PTH, fasting glucose, sleep, BMI/sun exposure variables (PMID 28882871, PMID 36643972, PMID 36863481, PMID 32062040, PMID 32360596); cross-level ecological exposure and individual outcome effect modifications exhibit group-level confounding and within-level correlation (PMID 10814658).
Partially Verified: “Different proportions of deficiency leading to solar-disease effect magnitude drift” is a candidate mechanism for heterogeneity; stratifiability of baseline 25(OH)D is jointly determined by latitude, skin pigmentation, supplementation, and GC genotype (PMID 33230496, PMID 31669447); the relationship between baseline 25(OH)D and effect modification has been detected multiple times within the vitamin D axis, but direction and magnitude vary by outcome.
To Be Verified: Explicit interaction term for “Solar Cycle Phase × Baseline 25(OH)D” has never been directly modeled; magnitude of stratification drift caused by “modifier moving with exposure” is unknown; whether cross-latitude gradients amplify interaction effects remains unmeasured; whether consistency across additive/multiplicative scales can serve as a preliminary screen for new interaction terms lacks systematic evaluation.
Related Reading
- Same Sun, Why Do Some Feel Afflicted and Others None? Effect Modification by Baseline Vitamin D Status
- Serum Vitamin D: How Much Weight Does the Solar Cycle Have as a Mediator Channel for Health?
- Cross-Latitude Multi-Center Direct Comparison of Solar Activity Effects
- Five Transmissions and Six Qi = Climate Cycle Medicine
- Research Pool: Environment-Life Frequency Interface
Evidence Level: B (Methodology and effect modification evidence are directly supported by PubMed; “Solar Cycle Phase × Baseline 25(OH)D Interaction Term” itself has no direct study, belonging to methodological extension argumentation)
References: PMID 15066682, PMID 22422832, PMID 28192563, PMID 23144464, PMID 16674808, PMID 29424028, PMID 22253321, PMID 19211620, PMID 28882871, PMID 36643972, PMID 36863481, PMID 32062040, PMID 32360596, PMID 10814658, PMID 28202713, PMID 39301110, PMID 33230496, PMID 28842142, PMID 31669447
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply